Dynacure
Module 2 du bio-incubateur de l’ESBS, Pôle API.
300 Boulevard Sébastien Brant, CS 10413
Illkirch
Cedex
F-67412
France
Website: http://www.dynacure.fr/
Email: info@dynacure.com
About Dynacure
Dynacure is a biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults. Dynacure’s Dyn101 development program is based on the modulation of the expression of the Dynamin 2 protein through the use of an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, the leading biopharmaceutical company in RNA-targeted drug discovery.YEAR FOUNDED:
2016
LEADERSHIP:
CEO: Stéphane Van Rooijen
COO: Frédéric Legros
Head of Development: Dr Leen Thielemans
Scientific Advisor: Belinda Cowling
Scientific Advisor: Scientific Advisor:
PRODUCTS
Please click here for Dynacure's products.
23 articles with Dynacure
-
Flamingo Therapeutics and Dynacure Announce Merger to Create Leading RNA Therapeutics Company Focused on Clinical Oncology
3/2/2023
Flamingo Therapeutics ("Flamingo") and Dynacure, announced today that the companies have signed a definitive merger agreement to combine their pipelines and expertise to create a leading oncology company.
-
Dynacure has ended its Unite-CNM Phase I/II trial on DYN101, an investigational therapy for the treatment of myotubular and centronuclear myopathies.
-
Biopharma companies are building momentum to carry them through the bulk of 2022. BioSpace takes a look at some of the recent announcements.
-
Dynacure Receives Fast Track Designation for DYN101, an Investigational Antisense Oligonucleotide for the Treatment of Myotubular and Centronuclear Myopathies
1/6/2022
Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies (CNM), a group of rare, debilitating, and life-threatening genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its lead product candidate, DYN101.
-
Dynacure to Present at 40th Annual J.P. Morgan Healthcare Conference
1/3/2022
Dynacure, a clinical stage biotechnology company focusing on Myotubular and Centronuclear Myopathies, a group of rare, debilitating and life-threatening genetic diseases, announced that Stephane van Rooijen, M.D., president & chief executive officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference.
-
Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku
11/10/2021
Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced that Dynacure and Nippon Shinyaku Co., Ltd. have entered a long-term strategic development and commercialization agreement.
-
Dynacure Announces FDA Acceptance of Investigational New Drug Application for DYN101 for Myotubular and Centronuclear Myopathies
6/9/2021
Dynacure announced that the US Food and Drug Administration has accepted its Investigational New Drug application for DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein, for the treatment of Myotubular and Centronuclear Myopathies.
-
Dynacure Recognizes Rare Disease Day 2021
2/26/2021
New online series of family stories from the global myotubular and centronuclear myopathy community highlights the challenges of those affected and their collective hopes for the future
-
Dynacure Announces Issuance of U.S. Patent for DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)
1/26/2021
Dynacure announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. US 10, 865, 414 related to DYN101, an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein, for the treatment of Myotubular and Centronuclear Myopathies.
-
Dynacure Announces Appointment of Jean M. Franchi to its Board of Directors
1/21/2021
Dynacure, a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options, announced the appointment of Jean M. Franchi to its Board of Directors.
-
Dynacure Announces New Program, DYN201, for Hereditary Spastic Paraplegia (HSP), a Rare Neurodegenerative Disease
10/13/2020
Dynacure acquires intellectual property from Paris Brain Institute to support DYN201 development
-
Dynacure Announces Presentations at Upcoming Investor Conferences
7/29/2020
Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that the company is presenting at several virtual investor conferences during August 2020.
-
Dynacure Announces Presentation at Jefferies Virtual Global Healthcare Conference
5/27/2020
Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced today that Stephane van Rooijen (M.D. MBA), Chief Executive Officer of Dynacure, will present a company overview at the Jefferies Virtual Global Healthcare Conference on June 3rd, 2020 at 8:00 am ET.
-
Dynacure Announces €50M ($55M) Series C Financing
4/2/2020
Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced the close of a €50 million Series C financing led by Perceptive Advisors.
-
Dynacure Announces First Patient Dosed in Phase 1 / 2 'UNITE-CNM' Study of DYN101 for the Treatment of Myotubular and Centronuclear Myopathies (CNM)
3/5/2020
Dynacure announced that the first patient has been dosed with DYN101 in a Phase 1 / 2 study called 'Unite-CNM'.
-
Dynacure to Present at 40th Annual Cowen Healthcare Conference
2/26/2020
Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, announced that the company will be presenting at the 40th Annual Cowen Healthcare Conference being held March 2nd-4th at the Boston Marriott Copley Place hotel.
-
Dynacure Presents New Preclinical Results on Muscle Targeting with Antisense Oligonucleotides at the 24th Annual International Congress of the World Muscle Society
10/2/2019
Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced two poster presentations at the 24th Annual International Congress of the World Muscle Society (WMS).
-
Dynacure to Present at Chardan's 3rd Annual Genetic Medicines Conference
9/11/2019
Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the company will be presenting at the 3rd Annual Chardan Genetic Medicines Conference being held October 7th-October 8th at the Westin Grand Central hotel in New York.
-
Dynacure Appoints David Garrett as Chief Financial Officer
9/3/2019
Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced the appointment of David Garrett, MBA, CPA, as Chief Financial Officer.
-
Dynacure Receives Orphan Drug Designation from the US FDA for DYN101, an Antisense Medicine to Treat Rare Disease 'Centronuclear Myopathies'
8/8/2019
Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2) for the treatment of Centronuclear Myopathies (CNM)